Isolating and purifying cells for therapy

Patent metadata

Field	Value
Publication number	US-11051733-B2
Application number	US-35698209-A
Country	US
Kind code	B2
Filing date	Jan 21, 2009
Priority date	Jan 18, 2008
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

The present invention provides methods and devices for isolating cells from a subject by circulating the subject's body fluid over an affinity moeity coupled matrix to isolate cells from a subject either ex vivo or in vivo. One aspect of the invention is directed to connecting a subject to a system capable of circulating the subject's body fluid through an affinity moiety coupled matrix, such that the affinity moiety coupled matrix is capable of binding to and extracting target cells from the body fluid, and then eluting the target cells from the affinity moiety. Another aspect of the invention is directed to the apparatus for isolating cells from a subject, comprising a blood circulation system with an arterial side blood circuit for extracting blood and flowing the blood over an affinity moiety coupled matrix that binds to and extracts target cells and a venous side blood circuit for returning the blood to the patient. The invention is also directed to in vivo seeding of biomatrials by implanting the affinity moiety coupled matrix in a subject to attract and bind the target cells in vivo.

First claim

What is claimed is:

1. A self-seeding, implantable scaffold for in vivo seeding and development of target cells comprising:
a three-dimensional, biomatrix scaffold having a supportive framework that allows the target cells to attach and grow, wherein the biomatrix scaffold comprises a decellularized matrix having an intact acellular infrastructure comprising a collagen network with interstitial distances suitable for cell-cell interactions, the decellularized matrix being sized and shaped for implantation at a vascular or cardiac target site to augment or replace a natural biostructure that requires repair or replacement; and
an affinity moiety with substantial affinity for a target stem cell population comprising endothelial progenitor cells expressing a CD133 marker, wherein the affinity moiety comprises a CD133 antibody incorporated into and covalently coupled to the decellularized matrix and is capable of attracting and binding to said CD133+ endothelial progenitor cells in vivo, following implantation at the target site, and the cells attracted by the CD133 antibody proliferate and develop on the matrix to form a laminar CD133+ endothelial progenitor cell layer.

2. The self-seeding scaffold of claim 1 , wherein said affinity moiety is covalently coupled to the decellularized matrix through a crosslinking agent.

3. The self-seeding scaffold of claim 1 , wherein the decellularized matrix comprises decellularized cardiac or vascular tissue.

4. The self-seeding scaffold of claim 1 , wherein the decellularized matrix comprises decellularized blood vessel or heart tissue.

5. The self-seeding scaffold of claim 1 , wherein the decellularized matrix is covalently coupled to the affinity moiety using a linker.

6. The self-seeding scaffold of claim 5 , wherein the linker is SPDP (N-succinimidyi-3-(2-pyridyldithio)propionate).

7. The self-seeding scaffold of claim 5 , wherein the linker is selected from the group consisting of (N-succinimidyi-3-(2-pyridyldithio)propionate (SPDP), 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC or EDAC), N-hydroxysulfosuccinimide (Sulfo-NHS), and N-hydroxysuccinimide (NHS).

8. The self-seeding scaffold of claim 1 , wherein said affinity moiety is a recombinant antibody.

9. The self-seeding scaffold of claim 1 , wherein the affinity moiety comprises a single chain antibody.

10. The self-seeding scaffold of claim 1 , wherein the affinity moiety is a chimeric antibody comprising an antibody and a matrix molecule.

11. The self-seeding scaffold of claim 1 , wherein the scaffold further comprises an affinity moiety that has substantial affinity for a CD34 marker.

12. The self-seeding scaffold of claim 1 , wherein the scaffold further comprises an affinity moiety that has substantial affinity for cells selected from the group consisting of stem cells, hematopoietic stem cells, embryonic stem cells, embryonic-like stem cells, mesenchymal stem cells, myeloid stem cell, neuronal stem cells, and adult stem cells.

13. The self-seeding scaffold of claim 1 , wherein the decellularized matrix is biodegradable.

14. The self-seeding scaffold of claim 1 , wherein the scaffold is sized and shaped for implantation as a vascular stent.

15. The self-seeding scaffold of claim 1 , wherein the scaffold is sized and shaped for implantation as a cardiac prosthesis.

Assignees

• Tillman Bryan
• Atala Anthony
• Yoo James
• Univ Wake Forest Health Sciences

Inventors

• Tillman Bryan
• Atala Anthony
• Yoo James

Classifications

• A61B5/150244

  Rods for actuating or driving the piston, i.e. the cylindrical body that sits inside the syringe barrel, typically with an air tight seal, and slides in the barrel to create a vacuum or to expel blood · CPC title

• A61K35/44

  Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells · CPC title

• A61M1/3679

  by absorption (A61M1/3675 takes precedence) · CPC title

• A61B5/15003

  for venous or arterial blood · CPC title

• A61B5/150755

  Blood sample preparation for further analysis, e.g. by separating blood components or by mixing · CPC title